{"id":760906,"date":"2023-05-31T07:04:43","date_gmt":"2023-05-31T11:04:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/"},"modified":"2023-05-31T07:04:43","modified_gmt":"2023-05-31T11:04:43","slug":"akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/","title":{"rendered":"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress"},"content":{"rendered":"

<\/p>\n

Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress<\/b><\/p>\n

Nearly two-thirds of adolescents saw clinically meaningful improvement in attention following treatment<\/i><\/p>\n

Improvements were nearly three times as large as those in the pivotal trial that supported EndeavorRx\u2019s FDA authorization for children with ADHD ages 8-12<\/i><\/p>\n

Akili has filed with FDA for potential EndeavorRx label expansion<\/i><\/p>\n

BOSTON–(BUSINESS WIRE<\/a>)–Akili, Inc.<\/a> (Nasdaq: AKLI), a leading digital medicine company, is presenting pivotal trial data on EndeavorRx\u00ae<\/sup> (AKL-T01) in adolescents with attention-deficit\/hyperactivity disorder (ADHD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach on May 31, 2023, and at the Elevate Psych Congress in Las Vegas on June 2-3, 2023. The poster presentations highlight results of Akili\u2019s STARS-ADHD-Adolescents label expansion trial evaluating the efficacy and safety of EndeavorRx in adolescents ages 13-17 with ADHD.<\/p>\n

\nThe multi-center open-label study enrolled 162 adolescents ages 13-17 with inattentive or combined-type ADHD. After four weeks of treatment with EndeavorRx, trial participants saw significant improvements across a wide range of clinical outcomes, including in their attention and ADHD-related symptoms.<\/p>\n

\n\u201cThe data being presented expand the evidence supporting the safety and efficacy of EndeavorRx to improve attention and functioning in adolescents with ADHD,\u201d said Scott Kollins, Ph.D., chief medical officer of Akili. \u201cTeenagers have been significantly impacted by our current mental health crisis, yet face substantial challenges in accessing effective treatment for ADHD. With our ongoing label expansion strategy, we aim to advance ADHD care management for people of all ages to break down these barriers and get treatment into the hands of patients in need.\u201d<\/p>\n

\nIn the STARS-ADHD-Adolescents trial, EndeavorRx demonstrated a statistically significant improvement in adolescents\u2019 attention function as measured by a change in the Attention Comparison Score (ACS) of the FDA-cleared Test of Variables of Attention (TOVA\u00ae<\/sup>), the trial\u2019s predefined primary efficacy endpoint. Nearly two-thirds (66%) of adolescents met the prespecified definition of clinical response on the TOVA-ACS. The magnitude of improvement in attention function in teenagers was nearly three times larger than what was observed in the STARS-ADHD pivotal trial in 8-12 year olds that served as the basis for EndeavorRx\u2019s FDA authorization. The mean change from baseline on the TOVA-ACS in adolescents was 2.6 (SD=3.8; P < 0.0001) as compared to 0.93 (p<0.001) in 8-12 year olds. In exploratory responder analyses, 24.7% of participants no longer had a measurable attention deficit following treatment, achieving a TOVA-ACS of at least 0, which is in the normative range.<\/p>\n

\nThere were also consistent clinical benefits seen across a range of secondary measures of ADHD-related symptoms and functioning. Adolescents using EndeavorRx saw significant improvement in the Attention Deficit Hyperactive Disorder Rating Scale-5 (ADHD-RS) inattention subscale and total scale scores (p<0.0001 for both). ADHD-RS is a clinician-administered questionnaire which uses information collected from the child’s caregiver. A prespecified responder analysis also showed that 27.1% of adolescents in the study demonstrated at least a 30% reduction in total scores on the ADHD-RS following EndeavorRx treatment, a finding similar to the STARS-ADHD trial in children 8-12 (24%). Statistically significant improvements were also observed for parent and child ratings of attention improvement, as well as parent ratings of function across a number of domains, including peer relationships, academic functioning, behavioral functioning, homework functioning, and self-esteem.<\/p>\n

\nIn the study, approximately half of the teenagers used EndeavorRx by itself and the other half used it in conjunction with stimulant medication. The benefits of EndeavorRx were comparable whether it was used alone or along with stimulants.<\/p>\n

\nConsistent with the favorable safety profile reported in previous studies of EndeavorRx, the treatment was shown to be safe in this study, with no serious adverse events observed. A total of 4 participants (2.5%) experienced any adverse events, all of which were anticipated and mild or moderate, including: frustration tolerance decreased (3 participants) and headache (1 participant).<\/p>\n

\nEndeavorRx is currently authorized for use in 8-12 year olds with ADHD. Based on these new data, Akili has filed with FDA to expand its current EndeavorRx label to include 13-17 year olds. In May, Akili announced<\/a> topline data from a successful pivotal study of EndeavorRx in adults with ADHD 18 years of age and older, demonstrating that improvements in both objective measures of attention and clinical outcomes surpassed those seen in both pediatric and adolescent patient populations.<\/p>\n

EndeavorRx Indication and Overview
\n
<\/b>EndeavorRx is the first-and-only FDA-authorized treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, the Test of Variables of Attention (TOVA\u00ae), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and\/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child\u2019s medication. The most common side effect observed in children in EndeavorRx\u2019s clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child\u2019s health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com<\/a>.<\/p>\n

About Akili
\n
<\/b>Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili\u2019s approach of leveraging technologies designed to directly target the brain establishes a new category of medicine \u2013 medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili\u2019s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili\u2019s belief that effective medicine can also be fun and engaging, Akili\u2019s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com<\/a>.<\/p>\n

Cautionary Note Regarding Forward-Looking Statements
\n<\/b>
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.<\/p>\n

\nThese forward-looking statements include, without limitation, statements in this press release related to: the potential expansion of our current pediatric market through our regulatory filing with FDA to seek a potential label expansion for EndeavorRx in ADHD to include adolescents ages 13-17. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the risk that prior results, such as signals of efficacy or safety observed from clinical trials will not continue or be repeated in EndeavorRx or our ongoing or planned clinical trials, or will be insufficient to support regulatory submissions or support or maintain marketing approval or label expansion approval in the United States or other jurisdictions, or that long-term adverse safety findings may be discovered; the risk that our products will not be further developed or commercialized successfully; the timing and results expected from our and our partners\u2019 clinical trials and our reliance on third parties for certain aspects of our business; our ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in our current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing the company\u2019s views as of any subsequent date. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230531005310\/en\/<\/a><\/span><\/p>\n

\n\u00a0<\/p>\n

Media:
\n<\/b>
Julie DiCarlo
\n
SVP, Communications
\n
PR@akiliinteractive.com<\/a><\/p>\n

KEYWORDS:<\/b> Florida Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Hardware Health Technology Technology Pharmaceutical Mental Health Teens Parenting Clinical Trials Electronic Games Other Technology Science Software Entertainment Consumer Research Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress Nearly two-thirds of adolescents saw clinically meaningful improvement in attention following treatment Improvements were nearly three times as large as those in the pivotal trial that supported EndeavorRx\u2019s FDA authorization for children with ADHD ages 8-12 Akili has filed with FDA for potential EndeavorRx label expansion BOSTON–(BUSINESS WIRE)–Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, is presenting pivotal trial data on EndeavorRx\u00ae (AKL-T01) in adolescents with attention-deficit\/hyperactivity disorder (ADHD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach on May 31, 2023, and at the Elevate Psych Congress in … <\/p>\n

Continue reading “Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-760906","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAkili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress Nearly two-thirds of adolescents saw clinically meaningful improvement in attention following treatment Improvements were nearly three times as large as those in the pivotal trial that supported EndeavorRx\u2019s FDA authorization for children with ADHD ages 8-12 Akili has filed with FDA for potential EndeavorRx label expansion BOSTON–(BUSINESS WIRE)–Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, is presenting pivotal trial data on EndeavorRx\u00ae (AKL-T01) in adolescents with attention-deficit\/hyperactivity disorder (ADHD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach on May 31, 2023, and at the Elevate Psych Congress in … Continue reading "Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-31T11:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress\",\"datePublished\":\"2023-05-31T11:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/\"},\"wordCount\":1528,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/\",\"name\":\"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-31T11:04:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/","og_locale":"en_US","og_type":"article","og_title":"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress - Market Newsdesk","og_description":"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress Nearly two-thirds of adolescents saw clinically meaningful improvement in attention following treatment Improvements were nearly three times as large as those in the pivotal trial that supported EndeavorRx\u2019s FDA authorization for children with ADHD ages 8-12 Akili has filed with FDA for potential EndeavorRx label expansion BOSTON–(BUSINESS WIRE)–Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, is presenting pivotal trial data on EndeavorRx\u00ae (AKL-T01) in adolescents with attention-deficit\/hyperactivity disorder (ADHD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach on May 31, 2023, and at the Elevate Psych Congress in … Continue reading \"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-31T11:04:43+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress","datePublished":"2023-05-31T11:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/"},"wordCount":1528,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/","name":"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-31T11:04:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230531005310r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akili-to-present-clinical-data-from-pivotal-trial-of-video-game-treatment-in-adolescents-with-adhd-at-2023-ascp-annual-meeting-and-elevate-psych-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=760906"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760906\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=760906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=760906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=760906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}